All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
Perl reports the results from a retrospective study evaluating clinical outcomes in patients with relapsed or refractory AML treated with midostaurin or sorafenib before receiving gilteritinib in the CHRYSALIS trial and in the ADMIRAL trial.
ESH 2019 | How will the use of FLT3 inhibitors evolve in the future?
Alexander Perl, University of Pennsylvania, describes the clinical use of FLT3 inhibitors in the relapsed/refractory setting.
1st NCRI AML academy meeting | Does current evidence support FLT3 maintenance therapy?
At the 1st NCRI AML academy meeting, Dr Steve Knapper spoke to us about the evidence surrounding the treatment of acute myeloid leukemia (AML) using FLT3...
Subscribe to get the best content related to AML delivered to your inbox